IP Library Granted Patent US 8,131,372
Granted Patent B2
US 8,131,372 · App. 11/688,178 · Granted Mar 6, 2012

Renal nerve stimulation method for treatment of patients

Assignee: Ardian, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,131,372
App. No.
11/688,178
Granted
Mar 6, 2012
Kind
B2
Abstract

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.

Claims (55)

1. A method for reducing blood pressure in a human patient, the method comprising:

positioning a nerve modulation device adjacent to a renal nerve of at least one kidney in a body of the patient; and

at least partially blocking the renal nerve of the kidney in the body of the patient by at least partially ablating the renal nerve,

wherein at least partially blocking the renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

2. The method of claim 1 , wherein positioning the nerve modulation device adjacent to the renal nerve further comprises positioning the nerve modulation device within a renal vasculature of the patient.

3. The method of claim 2 , wherein positioning the nerve modulation device within the renal vasculature of the patient further comprises positioning the nerve modulation device within a renal artery of the patient.

4. The method of claim 2 , wherein positioning the nerve modulation device within the renal vasculature of the patient further comprises positioning the nerve modulation device within a renal vein of the patient.

5. The method of claim 2 , wherein positioning the nerve modulation device within the renal vasculature of the patient further comprises positioning a catheter within the renal vasculature of the patient.

6. The method of claim 5 , wherein positioning the catheter within the renal vasculature of the patient further comprises positioning an electrode within the renal vasculature of the patient.

7. The method of claim 6 , wherein positioning the electrode within the renal vasculature further comprises positioning a unipolar electrode within the renal vasculature of the patient.

8. The method of claim 6 , wherein at least partially ablating the renal nerve further comprises delivery of an electric field via the electrode to affect the renal nerve.

9. The method of claim 8 further comprising monitoring with a sensor at least one condition of the patient.

10. The method of claim 9 further comprising regulating delivery of the electric field based on a monitored condition of the patient.

11. The method of claim 6 , wherein at least partially ablating the renal nerve further comprises heating the renal nerve with energy delivered via the electrode.

12. The method of claim 11 , wherein the energy delivered via the electrode comprises RF energy.

13. The method of claim 6 , wherein positioning the electrode within the renal vasculature of the patient further comprises positioning a bipolar electrode pair within the renal vasculature of the patient.

14. The method of claim 6 , wherein positioning the electrode within the renal vasculature of the patient further comprises contacting the electrode with a wall of the renal vasculature of the patient.

15. The method of claim 1 , wherein at least partially ablating the renal nerve further comprises at least partially ablating the renal nerve by transferring thermal energy.

16. The method of claim 15 , wherein at least partially ablating the renal nerve by transferring thermal energy further comprises heating the renal nerve.

17. The method of claim 16 , wherein heating the renal nerve further comprises heating the renal nerve with RF energy.

18. The method of claim 15 , wherein at least partially ablating the renal nerve by transferring thermal energy further comprises cooling the renal nerve.

19. The method of claim 1 , wherein positioning the nerve modulation device adjacent to a renal nerve of the patient further comprises positioning a drug delivery device adjacent to the renal nerve.

20. The method of claim 19 , wherein at least partial ablation of the renal nerve further comprises at least partial ablation of the renal nerve via delivery of chemical agents to the renal nerve.

21. The method of claim 1 , wherein treating the patient further comprises treating the patient for a condition chosen from the group consisting of heart failure, acute myocardial infarction, cardio-renal disease, chronic renal failure, end stage renal disease, proteinuria, hypertension, neuro-hormonal imbalance, elevated sympathetic activity and combinations thereof.

22. A method for treating at least one of heart failure, acute myocardial infarction, cardio-renal disease, chronic renal failure, end stage renal disease, proteinuria, hypertension, neuro-hormonal imbalance, and elevated sympathetic activity in a human patient, the method comprising:

intravascularly positioning a distal section of an electrical nerve modulation device adjacent to a renal nerve of at least one kidney of the patient and a proximal section of the electrical nerve modulation device outside of the patient;

at least partially ablating the renal nerve of the kidney via the electrical nerve modulation device; and

removing the distal section of the electrical nerve modulation device from the patient.

23. The method of claim 22 , wherein positioning the electrical nerve modulation device adjacent the renal nerve of the patient further comprises positioning the electrical nerve modulation device within a renal vasculature of the patient.

24. The method of claim 23 , wherein positioning the electrical nerve modulation device within the, renal vasculature of the patient further comprises positioning the electrical nerve modulation device within a renal artery of the patient.

25. The method of claim 23 , wherein positioning the electrical nerve modulation device within the renal vasculature of the patient further comprises positioning the electrical nerve modulation device within a renal vein of the patient.

26. The method of claim 23 , wherein positioning the electrical nerve modulation device within the renal vasculature of the patient further comprises positioning an electrode within the renal vasculature of the patient.

27. The method of claim 26 , wherein positioning the electrode within the renal vasculature of the patient further comprises positioning a unipolar electrode within the renal vasculature of the patient.

28. The method of claim 26 , wherein at least partially ablating the renal nerve further comprises delivery of an electric field via the electrode to affect the renal nerve.

29. The method of claim 26 , wherein at least partially ablating the renal nerve further comprises heating the renal nerve with energy delivered via the electrode.

30. The method of claim 29 , wherein the energy delivered via the electrode comprises RF energy.

31. The method of claim 29 further comprising monitoring at least one condition of the patient with a sensor.

32. The method of claim 31 further comprising regulating delivery of the electric field based on a monitored condition of the patient.

33. The method of claim 26 , wherein positioning the electrode within the renal vasculature of the patient further comprises positioning a bipolar electrode pair within the renal vasculature of the patient.

34. The method of claim 26 , wherein positioning the electrode within the renal vasculature of the patient further comprises contacting the electrode with a wall of the renal vasculature of the patient.

35. The method of claim 22 , wherein at least partially ablating the renal nerve further comprises at least partial ablation of the renal nerve by transferring thermal energy.

36. The method of claim 35 , wherein at least partially ablating the renal nerve by transferring thermal energy further comprises heating the renal nerve.

37. The method of claim 36 , wherein heating of the renal nerve further comprises heating of the renal nerve with RF energy.

38. The method of claim 35 , wherein at least partially ablating the renal nerve by transferring thermal energy further comprises cooling the renal nerve.

39. A method for treatment of a human patient via renal denervation, the method comprising:

intravascularly positioning a renal denervation catheter proximate to a renal nerve of at least one kidney in a body of the patient; and

at least partially ablating the renal nerve of the kidney in the body of the patient,

wherein at least partially ablating the renal nerve results in a therapeutically beneficial reduction in central sympathetic overactivity of the patient.

40. The method of claim 39 , wherein at least partially ablating the renal nerve further comprises reducing afferent neural signals along the renal nerve.

41. The method of claim 39 , wherein at least partially ablating the renal nerve further comprises reducing efferent neural signals along the renal nerve.

42. The method of claim 39 , wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of hypertension in the patient.

43. The method of claim 39 , wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of heart failure in the patient.

44. The method of claim 39 , wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of chronic renal failure in the patient.

45. The method of claim 39 , wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of chronic impaired renal function in the patient.

46. The method of claim 39 , wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of acute myocardial infarction in the patient.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE PREVIOUSLY RECORDED ASSIGNMENT, TO CORRECT THE PATENT NUMBER: FROM 7131372 TO 8131372. PREVIOUSLY RECORDED ON REEL 030285 FRAME 0723. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER: 8131372. Recorded Apr 29, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030304/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030285/0723 →
CHANGE OF NAME Recorded Apr 25, 2013
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 030293/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2010
From: GELFAND, MARK; LEVIN, HOWARD R.
To: G&L CONSULTING, LLC
Reel/Frame 024611/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2010
From: G&L CONSULTING, LLC
To: FOUNDRY NEWCO 8, INC.
Reel/Frame 024611/0061 →
CHANGE OF NAME Recorded Jun 29, 2010
From: FOUNDRY NEWCO 8, INC.
To: ARDIAN, INC.
Reel/Frame 024611/0090 →
Continuity (6)
Continuation 11144173 · Jun 3, 2005
Continuation 10408665 · Apr 8, 2003
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60442970 · Jan 29, 2003
Related Publication 20070173899A1 · Jul 26, 2007